drugset / Trial / NCT06764160
Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label, single-arm, multi-center study to evaluate the efficacy, safety, PK, PD, and immunogenicity of eculizumab in Chinese participants with refractory gMG. Approximately 15 participants will be enrolled in the study.
Timeline
- Start
- 2025-01-06
- Primary completion
- 2025-12-29
- Completion
- 2025-12-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eculizumab | Monoclonal antibody | — | Intravenous |